A prospective cohort study of treatment efficacy of biologics for severe asthma in children and young adults for prevention of airway remodeling

A prospective cohort study of treatment efficacy of biologics for severe asthma in children and young adults for prevention of airway remodeling - A prospective cohort study of treatment efficacy of biologics for severe asthma in children and young adults for prevention of airway remodeling

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050429

Enrollment

Registered

2023-03-01

Start date

2023-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with asthma between the ages of 6 and 39 years who require the administration of a biologics. 2) Those whose FEV1, FEV1/FVC, and V50 have been measured at least once a year, and at least 3 times in the last 2 years.

Exclusion criteria

Exclusion criteria: 1) Those who have already started and are stable on the use of the following biologics.(omalizumab, mepolizumab, venlalizumab, dupilumab, tezepelumab) 2) Those who have requested to opt out of this study.

Design outcomes

Primary

Measure	Time frame
Changes in respiratory function before and after administration of each biologic	—

Secondary

Measure	Time frame
1. Changes in Clinical Symptoms Before and After Introduction of Biological Agents 2. Biomarker changes before and after introduction of biologics	—

Countries

Japan

Contacts

Public ContactTakahiro Nishida

National Mie Hospital Department of Pediatrics and Allergy

t_nishida0930@yahoo.co.jp059-232-2531

Outcome results